StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) KPIs and segments

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)

Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Abbott Laboratories · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

Nhìn nhanh KPI của Abbott Laboratories: 64 chỉ số vận hành, trong đó có Continuous Glucose Monitoring (CGM, Diabetes Care Division và Electrophysiology Division, lấy từ 217 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Medical Devices($M)2
5,8535,5395,6755,4485,3694,8955,0524,7474,7344,4534,443
International($M)
3,1733,0163,0702,9272,8662,5562,6992,5312,5492,4192,378
United States($M)
2,6802,5232,6052,5212,5032,3392,3532,2162,1852,0342,065
Diagnostic Products($M)2
3,0922,1802,4572,2532,1732,0542,5202,4122,1952,2142,534
United States($M)
1,6609059678868118711,0551,0328129311,020
International($M)
1,4321,2751,4901,3671,3621,1831,4651,3801,3831,2831,514
Nutritional Products($M)2
2,1442,0171,9402,1532,2122,1462,1292,0662,1502,0682,038
International($M)
1,2731,1731,1341,2651,2551,1911,2011,1161,2171,1901,178
United States($M)
871844806888957955928950933878860
Established Pharmaceuticals($M)2
1,4991,4261,3821,5111,3831,2601,2681,4061,2941,2261,222
International($M)
1,4991,4261,3821,5111,3831,2601,2681,4061,2941,2261,222
United States($M)
00000000000
International($M)
7,3776,8907,0767,0706,8666,1906,6336,4336,4436,1186,292
United States($M)
5,2164,2744,3834,2994,2764,1684,3414,2023,9343,8463,949
Medical Devices($M)
1,9691,8931,9781,8291,7961,6091,7731,5131,5071,3601,501
Diagnostic Products($M)
499335609400372359611558430474713
Established Pharmaceuticals($M)
382365255391346298271380315267254
Nutritional Products($M)
368311386360418394443312373377361
Medical Devices($M)
3,9283,7253,6813,6113,2973,1423,1072,906
Diagnostic Products($M)
1,5609389639499021,1329921,026
Nutritional Products($M)
9969289301,0571,0229151,002980
Established Pharmaceuticals($M)
849782797752691762703642
Established Pharmaceuticals($M)
-36-20-59-38-39-33-65-52-37-29
Nutritional Products($M)
-46-40-71-71-81-79-100-106-103-73
Diagnostic Products($M)
-157-128-292-168-166-135-283-183-169-123
Medical Devices($M)
-185-147-217-140-145-156-186-151-158-135
Medical Devices($M)
11,40610,98310,68910,57610,55510,0349,4729,029
Diagnostic Products($M)
9,7099,6318,2738,2018,1777,8407,6787,767
Nutritional Products($M)
5,2784,9034,7914,8914,9104,6354,4044,270
Established Pharmaceuticals($M)
3,8193,6653,5403,7303,7323,4483,0873,118
Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M)($M)2
2,1002,0002,0002,0001,9001,7001,8001,7001,6001,5001,400
CGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%)(%)
7.7%9.5%7.6%12.2%17.2%19.6%21.6%22.8%20.7%20.4%23.3%
CGM (FreeStyle Libre) — Reported Sales Growth (%)(%)
7.3%11.0%14.2%15.0%20.5%21.4%18.3%22.7%19.1%18.4%22.4%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M)($M)5
2,1852,1882,0802,1332,0571,9811,8271,8631,7251,6481,5691,552
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Organic / Comparable Sales Growth (%)(%)
6.7%9.0%7.4%11.7%16.2%18.5%19.8%20.6%19.1%18.2%20.7%20.7%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Reported Sales Growth (%)(%)
6.2%10.5%13.8%14.5%19.3%20.2%16.5%20.1%17.1%15.8%19.5%22.0%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Foreign Exchange Impact on Sales Growth (%)(%)
2.8%3.1%1.7%-3.3%-0.5%-2.0%-2.4%-1.2%1.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — U.S. Revenue ($M)($M)2
872862822843796794748734673637589601
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Organic / Comparable Sales Growth (%)(%)
9.4%8.6%9.8%14.9%18.4%24.5%27.1%22.0%23.6%26.3%22.8%28.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Reported Sales Growth (%)(%)
9.4%8.6%9.8%14.9%18.4%24.5%27.1%22.0%23.6%26.3%22.8%28.3%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — International Revenue ($M)($M)2
1,3131,3261,2581,2901,2611,1871,0791,1291,0521,011980951
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%)(%)
4.9%9.2%5.7%9.6%14.7%14.7%15.4%19.7%16.5%13.7%19.6%16.2%
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Reported Sales Growth (%)(%)
4.2%11.7%16.6%14.2%19.9%17.5%10.1%18.8%13.3%10.0%17.6%18.4%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M)($M)5
873861788730705700629643610627587593
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%)(%)
15.5%13.4%12.5%12.5%13.7%10.3%9.9%8.8%14.3%16.7%18.4%21.2%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Reported Sales Growth (%)(%)
15.0%14.0%16.7%13.5%15.6%11.5%7.3%8.3%12.2%13.3%16.2%21.5%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Foreign Exchange Impact on Sales Growth (%)(%)
1.0%1.9%1.2%-2.6%-0.5%-2.1%-3.4%-2.2%0.3%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — U.S. Revenue ($M)($M)2
429420378340322322299300285287269279
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Organic / Comparable Sales Growth (%)(%)
18.1%15.9%13.7%13.1%13.2%12.2%11.1%7.7%15.8%16.8%13.1%15.0%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Reported Sales Growth (%)(%)
18.1%15.9%13.7%13.1%13.2%12.2%11.1%7.7%15.8%16.8%13.1%15.0%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — International Revenue ($M)($M)2
444441410390383378330343325340318314
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Organic / Comparable Sales Growth (%)(%)
13.1%11.1%11.2%11.9%14.1%8.8%8.8%9.8%13.0%16.7%23.0%27.3%
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Reported Sales Growth (%)(%)
12.2%12.3%19.6%13.9%17.6%10.9%4.0%8.8%9.2%10.5%18.9%28.0%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Worldwide Revenue ($M)($M)5
592597578675635636577609558564515498
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Organic / Comparable Sales Growth (%)(%)
6.9%5.7%6.8%8.7%11.3%11.7%14.7%22.6%16.5%15.6%13.0%11.4%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Reported Sales Growth (%)(%)
1.9%2.7%9.0%10.8%13.6%13.0%11.9%22.4%14.6%13.2%11.7%12.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Foreign Exchange Impact on Sales Growth (%)(%)
2.1%2.3%1.3%-2.8%-0.2%-1.9%-2.4%-1.3%1.5%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — U.S. Revenue ($M)($M)2
228225224304297289282290270258233231
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Organic / Comparable Sales Growth (%)(%)
-2.3%-0.9%-3.6%4.8%10.1%12.2%20.9%25.7%21.1%17.9%10.8%7.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Reported Sales Growth (%)(%)
-11.1%-9.8%-9.5%4.8%10.1%12.2%20.9%25.7%21.1%17.9%10.8%7.9%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — International Revenue ($M)($M)2
364372354371338347295319288306282267
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Organic / Comparable Sales Growth (%)(%)
13.5%10.2%15.0%12.3%12.4%11.4%9.6%20.0%12.6%13.8%14.8%14.7%
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%)(%)
12.2%12.1%25.2%16.3%16.9%13.7%4.6%19.5%9.2%9.4%12.5%17.6%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Worldwide Revenue ($M)($M)5
752743684705686673585624597607562582
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%)(%)
10.0%9.5%12.5%11.5%13.0%9.8%6.1%7.2%7.0%5.9%7.5%12.1%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Reported Sales Growth (%)(%)
9.7%10.4%17.0%13.1%15.0%10.9%4.0%7.1%5.9%4.2%6.8%13.3%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Foreign Exchange Impact on Sales Growth (%)(%)
1.6%2.0%1.1%-2.1%-0.1%-1.1%-1.7%-0.7%1.2%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — U.S. Revenue ($M)($M)2
380377339340350340304303288292271285
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%)(%)
9.0%10.7%11.5%12.8%21.1%16.5%12.3%6.0%6.0%8.5%4.5%12.0%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Reported Sales Growth (%)(%)
9.0%10.7%11.5%12.8%21.1%16.5%12.3%6.0%6.0%8.5%4.5%12.0%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — International Revenue ($M)($M)2
372366345365336333281321309315291297
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Organic / Comparable Sales Growth (%)(%)
11.0%8.3%13.5%10.2%5.5%3.6%0.3%8.4%7.9%3.7%10.3%12.1%
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%)(%)
10.4%10.0%22.9%13.4%9.3%5.7%-3.7%8.2%5.7%0.4%9.0%14.5%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Worldwide Revenue ($M)($M)5
387401389375366368339331322321305301
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Organic / Comparable Sales Growth (%)(%)
6.0%8.7%12.2%12.1%12.1%14.0%12.4%9.6%14.4%8.9%8.4%15.4%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Reported Sales Growth (%)(%)
5.8%9.0%14.6%13.2%13.3%14.7%11.4%9.9%14.0%8.6%8.5%16.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Foreign Exchange Impact on Sales Growth (%)(%)
1.1%1.2%0.7%-1.0%0.3%-0.4%-0.3%0.1%1.2%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — U.S. Revenue ($M)($M)2
303313292283280282262253252244237227
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Organic / Comparable Sales Growth (%)(%)
8.4%10.9%11.4%11.7%10.7%15.8%10.6%11.5%16.7%7.7%8.7%13.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Reported Sales Growth (%)(%)
8.4%10.9%11.4%11.7%10.7%15.8%10.6%11.5%16.7%7.7%8.7%13.6%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — International Revenue ($M)($M)2
848897928686777870776874
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Organic / Comparable Sales Growth (%)(%)
-1.6%1.3%14.9%13.4%17.2%8.4%19.1%4.1%6.6%12.8%7.1%21.4%
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Reported Sales Growth (%)(%)
-2.7%3.0%25.2%17.9%22.6%11.2%14.3%5.0%5.2%11.4%7.7%26.6%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M)($M)5
786803777783745757710725699724689677
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%)(%)
5.7%5.1%4.9%6.5%4.7%3.5%5.7%6.8%4.9%1.2%5.8%4.5%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%)(%)
5.4%6.1%9.5%8.0%6.6%4.5%3.0%7.1%3.9%1.3%11.7%12.0%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Foreign Exchange Impact on Sales Growth (%)(%)
1.5%1.9%1.0%-2.7%0.3%-1.0%-2.0%-1.0%1.1%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — U.S. Revenue ($M)($M)2
290294291287280283268269258275254245
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Organic / Comparable Sales Growth (%)(%)
3.4%3.9%8.6%6.5%8.5%3.0%5.5%9.7%2.8%-0.8%-1.8%-2.5%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Reported Sales Growth (%)(%)
3.4%3.9%8.6%6.5%8.5%3.0%5.5%9.7%2.8%4.3%16.4%14.8%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M)($M)2
496509486496465474442456441449435432
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Organic / Comparable Sales Growth (%)(%)
7.1%5.8%2.7%6.6%2.5%3.8%5.8%5.2%6.2%2.5%9.9%8.3%
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Reported Sales Growth (%)(%)
6.7%7.5%10.0%8.9%5.5%5.4%1.6%5.7%4.5%-0.4%9.1%10.4%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M)($M)5
251260243274254254228257236243226240
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Organic / Comparable Sales Growth (%)(%)
-1.1%1.2%4.1%5.6%6.8%4.3%2.2%8.4%5.2%8.2%17.4%18.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Reported Sales Growth (%)(%)
-1.2%2.0%6.8%6.5%7.6%4.6%1.0%7.7%3.8%7.0%15.3%18.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Foreign Exchange Impact on Sales Growth (%)(%)
0.9%0.8%0.3%-1.2%-0.7%-1.4%-1.2%-2.1%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — U.S. Revenue ($M)($M)2
185189177208196193176204190192181197
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Organic / Comparable Sales Growth (%)(%)
-5.6%-2.1%0.7%1.9%3.3%0.4%-2.8%4.2%0.8%3.7%16.8%20.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%)(%)
-5.6%-2.1%0.7%1.9%3.3%0.4%-2.8%4.2%0.8%3.7%16.8%20.8%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — International Revenue ($M)($M)2
667166665861525346514543
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%)(%)
13.9%11.3%15.5%19.6%21.2%18.7%22.7%27.8%25.7%28.4%19.6%10.2%
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%)(%)
13.6%14.7%27.2%23.8%24.9%20.4%16.3%23.9%17.8%21.7%9.8%10.2%
Medical Devices Segment Total — Worldwide Revenue ($M)($M)8
5,8265,8535,5395,6755,4485,3694,8955,0524,7474,7344,4534,443
Medical Devices Segment Total — Organic / Comparable Sales Growth (%)(%)
7.8%8.4%8.5%10.4%12.5%12.2%12.6%14.0%13.3%12.1%14.3%15.4%
Medical Devices Segment Total — Reported Sales Growth (%)(%)
6.9%9.0%13.2%12.3%14.8%13.4%9.9%13.7%11.7%10.2%14.2%17.5%
Medical Devices Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)
1.9%2.3%1.2%-2.7%-0.3%-1.6%-2.2%-1.2%1.0%
Medical Devices Segment Total — U.S. Revenue ($M)($M)2
2,6872,6802,5232,6052,5212,5032,3392,3532,2162,1852,0342,065
Medical Devices Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)
7.6%8.0%8.7%10.7%13.8%14.6%15.0%14.0%14.2%13.5%12.1%15.5%
Medical Devices Segment Total U.S. — Reported Sales Growth (%)(%)
6.6%7.0%7.9%10.7%13.8%14.6%15.0%14.0%14.2%14.2%14.4%17.6%
Medical Devices Segment Total — International Revenue ($M)($M)2
3,1393,1733,0163,0702,9272,8662,5562,6992,5312,5492,4192,378
Medical Devices Segment Total International — Organic / Comparable Sales Growth (%)(%)
8.0%8.7%8.3%10.1%11.3%10.1%10.5%14.0%12.5%10.9%16.1%15.4%
Medical Devices Segment Total International — Reported Sales Growth (%)(%)
7.2%10.7%18.0%13.7%15.6%12.4%5.7%13.5%9.6%7.0%14.0%17.5%
Medical Devices — Remaining Performance Obligations / Contract Backlog ($M)($M)
455429444436427423440466493495478
Medical Devices — Segment Research & Development Expense ($M)($M)
470444460462430401391408379368
Medical Devices — Segment Property & Equipment Additions ($M)($M)
185147217140145156186151158135
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M)($M)7
1,4381,4181,2721,4611,3641,3581,1771,3871,3141,3291,2051,370
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Organic / Comparable Sales Growth (%)(%)
5.4%3.2%3.3%3.6%2.2%1.6%0.9%3.8%4.3%8.6%5.9%9.1%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Reported Sales Growth (%)(%)
5.4%4.4%8.1%5.3%3.8%2.2%-2.3%1.3%2.8%2.0%8.4%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Foreign Exchange Impact on Sales Growth (%)(%)
1.7%1.6%0.6%-3.2%-2.5%-4.3%-5.8%-3.9%-0.7%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — U.S. Revenue ($M)($M)2
389377347376366351332363332327310326
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Organic / Comparable Sales Growth (%)(%)
6.3%7.5%4.5%3.6%10.4%7.3%7.1%11.9%4.8%5.3%7.7%8.8%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Reported Sales Growth (%)(%)
6.3%7.5%4.5%3.6%10.4%7.3%7.1%11.6%4.5%5.1%7.3%8.3%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — International Revenue ($M)($M)2
1,0491,0419251,0859981,0078451,0249821,0028951,044
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Organic / Comparable Sales Growth (%)(%)
5.1%1.7%2.8%3.6%-0.6%-0.3%-1.3%1.5%4.4%9.9%5.7%10.0%
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Reported Sales Growth (%)(%)
5.1%3.4%9.5%5.9%1.6%0.5%-5.6%-1.9%-1.5%2.1%0.2%8.4%
Core Laboratory — Organic Sales Growth Excl. COVID-19 Testing (%)(%)
4.0%4.5%8.8%6.2%9.7%
Core Laboratory — COVID-19 Testing Sales ($M)($M)2
23234
Core Laboratory — U.S. COVID-19 Testing Sales ($M)($M)
11111
Core Laboratory — International COVID-19 Testing Sales ($M)($M)
12123
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M)($M)3
9689199600
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%)(%)
13.8%13.3%13.4%
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — U.S. Revenue ($M)($M)1
93889093
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) U.S. — Organic / Comparable Sales Growth (%)(%)
13.9%13.3%13.2%
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — International Revenue ($M)($M)1
30293
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) International — Organic / Comparable Sales Growth (%)(%)
12.1%13.8%19.2%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M)($M)4
899755812815877
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Organic / Comparable Sales Growth (%)(%)
0.9%-8.0%-9.6%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Reported Sales Growth (%)(%)
1.1%-7.3%-7.4%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — U.S. Revenue ($M)($M)2
526393465
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Organic / Comparable Sales Growth (%)(%)
1.1%-14.5%-13.8%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Reported Sales Growth (%)(%)
1.1%-14.5%-13.8%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — International Revenue ($M)($M)2
373362347
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Organic / Comparable Sales Growth (%)(%)
0.7%0.5%-2.7%
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Reported Sales Growth (%)(%)
1.0%2.0%2.8%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M)($M)7
697600544613849824583741862
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%)(%)
-18.1%-27.7%-6.8%-16.1%-1.0%-3.0%-19.8%-38.7%-49.2%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%)(%)
-17.8%-27.3%-6.7%-17.3%-1.6%-4.4%-21.3%-39.5%-49.3%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%)(%)
0.3%0.4%0.1%-1.2%-0.6%-1.4%-1.5%-0.8%-0.1%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M)($M)2
445373321399554560345481543
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Organic / Comparable Sales Growth (%)(%)
-19.7%-33.5%-7.1%-16.9%30.0%-1.0%-6.6%6.9%-29.2%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%)(%)
-19.7%-33.5%-7.1%-16.9%2.1%-0.2%-32.1%-46.9%-55.3%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — International Revenue ($M)($M)2
252227223214295264238260319
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Organic / Comparable Sales Growth (%)(%)
-14.9%-15.6%-6.3%-14.6%-0.6%2.8%11.0%3.5%18.6%
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Reported Sales Growth (%)(%)
-14.1%-14.2%-6.1%-17.9%-7.9%-12.2%2.1%-18.3%-34.4%
Rapid Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%)
16.4%0.4%0.4%5.6%-13.7%
Rapid Diagnostics — COVID-19 Testing Sales ($M)($M)2
17225997197277
Rapid Diagnostics — U.S. COVID-19 Testing Sales ($M)($M)
13220366149218
Rapid Diagnostics — International COVID-19 Testing Sales ($M)($M)
4056314859
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M)($M)7
141131123122137128127129153
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%)(%)
1.1%0.8%-3.4%-3.5%-10.2%-2.1%-9.4%-11.7%-14.9%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Reported Sales Growth (%)(%)
3.2%2.6%-2.7%-5.9%-10.5%-3.6%-10.3%-11.9%-14.6%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Foreign Exchange Impact on Sales Growth (%)(%)
2.1%1.8%0.7%-2.4%-0.3%-1.5%-0.9%-0.2%0.3%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — U.S. Revenue ($M)($M)2
393635403837334244
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%)(%)
2.9%-1.5%5.5%-4.4%-7.2%4.5%-19.0%6.2%-12.6%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Reported Sales Growth (%)(%)
2.9%-1.5%5.5%-4.4%-13.9%-2.8%-22.5%-10.6%-27.7%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M)($M)2
10295888299919487109
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Organic / Comparable Sales Growth (%)(%)
0.4%1.7%-6.5%-3.1%-7.5%0.8%-3.6%8.2%
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%)(%)
3.3%4.3%-5.6%-6.7%-9.1%-3.9%-4.9%-12.5%-7.8%
Molecular Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%)
-7.4%1.8%-5.6%-0.8%1.7%
Molecular Diagnostics — COVID-19 Testing Sales ($M)($M)2
23347
Molecular Diagnostics — U.S. COVID-19 Testing Sales ($M)($M)
12235
Molecular Diagnostics — International COVID-19 Testing Sales ($M)($M)
11112
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M)($M)5
158158148142147146156139149
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Organic / Comparable Sales Growth (%)(%)
7.1%7.8%-5.2%3.2%-1.4%4.6%10.0%3.6%13.0%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Reported Sales Growth (%)(%)
7.5%8.2%-5.1%2.4%-1.3%4.4%9.9%3.7%13.6%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%)(%)
0.4%0.4%0.1%-0.8%0.1%-0.2%-0.1%0.1%0.6%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — U.S. Revenue ($M)($M)2
10711110410010010310798107
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Organic / Comparable Sales Growth (%)(%)
6.5%7.9%-2.0%1.5%-6.1%6.0%8.1%5.6%20.7%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Reported Sales Growth (%)(%)
6.5%7.9%-2.0%1.5%-6.1%6.0%8.1%5.6%20.7%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — International Revenue ($M)($M)2
514744424743494142
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%)(%)
8.3%7.7%-12.1%7.3%10.7%1.3%14.5%-0.8%-2.9%
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Reported Sales Growth (%)(%)
9.8%8.9%-11.9%4.4%11.0%0.7%14.1%-0.6%-1.0%
Global COVID-19 Testing-Related Sales ($M)($M)2
89695584176265102204288
Diagnostics Segment — Organic Sales Growth Excl. COVID-19 Testing (%)(%)
-0.2%0.4%0.8%6.1%3.3%5.9%5.4%2.2%
Diagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%)(%)
-3.4%-8.2%-2.2%-5.1%-1.9%-7.4%-20.9%-24.5%
Diagnostics Segment Total — Worldwide Revenue ($M)($M)8
3,3053,0922,1802,4572,2532,1732,0542,5202,4122,1952,2142,534
Diagnostics Segment Total — Organic / Comparable Sales Growth (%)(%)
6.4%2.9%1.8%-3.6%-7.8%-1.4%-4.9%1.0%1.4%-1.5%-15.5%-22.3%
Diagnostics Segment Total — Reported Sales Growth (%)(%)
46.7%42.3%6.1%-2.5%-6.6%-1.0%-7.2%-0.6%-1.5%-5.3%-17.6%-22.7%
Diagnostics Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)
1.1%1.2%0.4%-2.3%-1.6%-2.9%-3.8%-2.1%-0.4%
Diagnostics Segment Total — U.S. Revenue ($M)($M)2
1,8531,6609059678868118711,0551,0328129311,020
Diagnostics Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)
8.4%4.0%2.0%-8.4%-14.1%-0.1%-6.4%15.9%2.4%-0.3%7.0%-10.7%
Diagnostics Segment Total U.S. — Reported Sales Growth (%)(%)
109.2%104.8%3.8%-8.4%-14.1%-0.1%-6.4%3.5%1.8%-15.5%-30.3%-38.8%
Diagnostics Segment Total — International Revenue ($M)($M)2
1,4521,4321,2751,4901,3671,3621,1831,4651,3801,3831,2831,514
Diagnostics Segment Total International — Organic / Comparable Sales Growth (%)(%)
4.0%1.6%1.6%-0.2%-3.1%-2.2%-3.8%0.8%3.8%9.5%4.4%10.9%
Diagnostics Segment Total International — Reported Sales Growth (%)(%)
6.2%5.1%7.8%1.8%-1.0%-1.5%-7.8%-3.4%-3.8%1.9%-5.1%-6.0%
Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M)($M)
6,2006,2006,1006,0005,9005,7005,5005,3004,8004,5004,400
Diagnostics — Segment Research & Development Expense ($M)($M)
268155147150154151174165162155
Diagnostics — Segment Property & Equipment Additions ($M)($M)
157128292168166135283183169123
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M)($M)5
1,0631,0259539029771,0541,0411,0009551,0591,009985
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Organic / Comparable Sales Growth (%)(%)
8.7%-3.1%-9.7%-10.1%2.4%0.2%4.9%2.5%-2.7%5.0%10.5%14.5%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Reported Sales Growth (%)(%)
8.8%-2.7%-8.5%-9.8%2.3%-0.4%3.2%1.5%-4.5%3.4%9.2%11.8%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Foreign Exchange Impact on Sales Growth (%)(%)
0.3%-0.1%-0.6%-1.7%-1.0%-1.8%-1.6%-1.3%-0.5%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — U.S. Revenue ($M)($M)2
577525511463520587588562568564514505
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Organic / Comparable Sales Growth (%)(%)
11.0%-10.7%-13.0%-17.7%-8.4%4.2%14.2%11.3%12.2%11.3%12.0%11.4%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Reported Sales Growth (%)(%)
11.0%-10.7%-13.0%-17.7%-8.4%4.2%14.2%11.3%12.2%11.3%12.0%11.4%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — International Revenue ($M)($M)2
486500442439457467453438387495495480
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Organic / Comparable Sales Growth (%)(%)
6.0%6.4%-5.3%-0.3%18.2%-4.5%-4.8%-6.7%-18.0%-1.0%8.9%17.9%
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Reported Sales Growth (%)(%)
6.4%7.3%-2.6%0.3%17.9%-5.7%-8.4%-8.9%-21.6%-4.4%6.4%12.3%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Worldwide Revenue ($M)($M)5
1,1991,1191,0641,0381,1761,1581,1051,1291,1111,0911,0591,053
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Organic / Comparable Sales Growth (%)(%)
1.8%-4.0%-5.9%-8.2%5.4%6.6%8.7%11.4%9.1%9.9%5.3%13.4%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Reported Sales Growth (%)(%)
2.0%-3.4%-3.6%-8.1%5.8%6.1%4.4%7.4%3.6%3.7%1.5%12.5%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Foreign Exchange Impact on Sales Growth (%)(%)
0.1%0.4%-0.5%-2.9%-2.3%-4.4%-5.4%-3.8%-0.9%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — U.S. Revenue ($M)($M)2
381346333343368370367366382369364355
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Organic / Comparable Sales Growth (%)(%)
3.5%-6.4%-9.2%-6.3%-3.8%0.2%4.8%8.1%11.5%0.8%3.0%4.0%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Reported Sales Growth (%)(%)
3.5%-6.4%-9.2%-6.3%-3.8%0.2%1.1%3.2%7.9%-1.2%3.0%4.0%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — International Revenue ($M)($M)2
818773731695808788738763729722695698
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Organic / Comparable Sales Growth (%)(%)
1.0%-2.8%-4.3%-9.1%10.2%9.8%10.6%13.0%8.0%14.7%6.4%18.9%
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Reported Sales Growth (%)(%)
1.3%-2.0%-0.9%-8.9%10.9%9.2%6.1%9.5%1.5%6.4%0.8%17.4%
Nutritional Products Segment Total — Worldwide Revenue ($M)($M)7
2,2622,1442,0171,9402,1532,2122,1462,1292,0662,1502,0682,038
Nutritional Products Segment Total — Organic / Comparable Sales Growth (%)(%)
4.9%-3.6%-7.7%-9.1%4.0%3.4%6.8%7.1%3.4%7.5%7.7%13.9%
Nutritional Products Segment Total — Reported Sales Growth (%)(%)
5.1%-3.1%-6.0%-8.9%4.2%2.9%3.8%4.5%-0.3%3.5%5.1%12.2%
Nutritional Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)
0.2%0.2%-0.5%-2.4%-1.7%-3.1%-3.6%-2.6%-0.7%
Nutritional Products Segment Total — U.S. Revenue ($M)($M)2
958871844806888957955928950933878860
Nutritional Products Segment Total U.S. — Organic / Comparable Sales Growth (%)(%)
7.9%-9.0%-11.6%-13.2%-6.5%2.6%10.4%10.0%11.9%6.9%8.1%8.2%
Nutritional Products Segment Total U.S. — Reported Sales Growth (%)(%)
7.9%-9.0%-11.6%-13.2%-6.5%2.6%8.8%8.0%10.4%6.0%8.1%8.2%
Nutritional Products Segment Total — International Revenue ($M)($M)2
1,3041,2731,1731,1341,2651,2551,1911,2011,1161,2171,1901,178
Nutritional Products Segment Total International — Organic / Comparable Sales Growth (%)(%)
2.8%0.6%-4.7%-5.9%13.0%4.0%4.2%4.9%-2.6%7.9%7.4%18.5%
Nutritional Products Segment Total International — Reported Sales Growth (%)(%)
3.1%1.4%-1.5%-5.6%13.3%3.1%0.1%2.0%-7.9%1.7%3.0%15.3%
Nutritional Products — Segment Research & Development Expense ($M)($M)
54545255545251535352
Nutritional Products — Segment Property & Equipment Additions ($M)($M)
46407171817910010610373
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Worldwide Revenue ($M)($M)4
1,1951,1641,0891,0461,0971,059965948994988928918
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Organic / Comparable Sales Growth (%)(%)
10.9%10.7%9.4%8.7%11.1%8.7%9.3%8.8%5.4%8.8%15.4%11.4%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Reported Sales Growth (%)(%)
9.0%9.8%12.9%10.3%10.3%7.3%4.0%3.3%0.7%-0.2%1.7%0.5%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Foreign Exchange Impact on Sales Growth (%)(%)
1.6%-0.8%-1.4%-5.3%-5.5%-4.7%-9.0%-13.7%-10.9%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — International Revenue ($M)($M)2
1,1951,1641,0891,0461,0971,059965948994988928918
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Organic / Comparable Sales Growth (%)(%)
10.9%10.7%9.4%8.7%11.1%8.7%9.3%8.8%5.4%8.8%15.4%11.4%
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Reported Sales Growth (%)(%)
9.0%9.8%12.9%10.3%10.3%7.3%4.0%3.3%0.7%-0.2%1.7%0.5%
Other Emerging & International Markets — Worldwide Revenue ($M)($M)4
419335337336414324295320412306298304
Other Emerging & International Markets — Organic / Comparable Sales Growth (%)(%)
1.6%2.1%7.9%1.9%-2.5%4.5%3.1%7.8%11.2%5.7%8.2%0.8%
Other Emerging & International Markets — Reported Sales Growth (%)(%)
1.1%3.7%14.1%5.0%0.6%5.9%-1.2%5.2%8.1%3.1%7.6%0.4%
Other Emerging & International Markets — Foreign Exchange Impact on Sales Growth (%)(%)
3.1%3.1%1.4%-4.3%-2.6%-3.1%-2.6%-0.6%-0.4%
Other Emerging & International Markets — International Revenue ($M)($M)2
419335337336414324295320412306298304
Other Emerging & International Markets International — Organic / Comparable Sales Growth (%)(%)
1.6%2.1%7.9%1.9%-2.5%4.5%3.1%7.8%11.2%5.7%8.2%0.8%
Other Emerging & International Markets International — Reported Sales Growth (%)(%)
1.1%3.7%14.1%5.0%0.6%5.9%-1.2%5.2%8.1%3.1%7.6%0.4%
Established Pharmaceutical Products Segment Total — Worldwide Revenue ($M)($M)6
1,6141,4991,4261,3821,5111,3831,2601,2681,4061,2941,2261,222
Established Pharmaceutical Products Segment Total — Organic / Comparable Sales Growth (%)(%)
8.4%8.7%9.0%7.0%7.1%7.7%7.8%8.5%7.0%8.1%13.7%8.8%
Established Pharmaceutical Products Segment Total — Reported Sales Growth (%)(%)
6.8%8.4%13.2%9.0%7.5%6.9%2.7%3.8%2.7%0.6%3.1%0.5%
Established Pharmaceutical Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%)
2.0%0.4%-0.8%-5.1%-4.7%-4.3%-7.5%-10.6%-8.3%
Established Pharmaceutical Products Segment Total — International Revenue ($M)($M)2
1,6141,4991,4261,3821,5111,3831,2601,2681,4061,2941,2261,222
Established Pharmaceutical Products Segment Total International — Organic / Comparable Sales Growth (%)(%)
8.4%8.7%9.0%7.0%7.1%7.7%7.8%8.5%7.0%8.1%13.7%8.8%
Established Pharmaceutical Products Segment Total International — Reported Sales Growth (%)(%)
6.8%8.4%13.2%9.0%7.5%6.9%2.7%3.8%2.7%0.6%3.1%0.5%
Established Pharmaceuticals — Segment Research & Development Expense ($M)($M)
48414942434245464441
Established Pharmaceuticals — Segment Property & Equipment Additions ($M)($M)
36205938393365523729
Total Company Consolidated Net Sales — Worldwide Revenue ($M)($M)6
13,01312,59311,16411,45911,36911,14210,35810,97410,63510,3779,96410,241
Total Company Consolidated Net Sales — Organic / Comparable Sales Growth (%)(%)
7.0%4.8%3.7%3.0%5.5%6.9%6.9%8.8%7.6%7.4%4.7%2.1%
Total Company Consolidated Net Sales — Reported Sales Growth (%)(%)
14.5%13.0%7.8%4.4%6.9%7.4%4.0%7.2%4.9%4.0%2.2%1.5%
Total Company Consolidated Net Sales — Foreign Exchange Impact on Sales Growth (%)(%)
1.4%1.4%0.5%-2.8%-1.4%-2.5%-3.5%-2.9%-0.8%
Total Company Consolidated Net Sales — U.S. Revenue ($M)($M)2
5,5045,2164,2744,3834,2994,2764,1684,3414,2023,9343,8463,949
Total Company Consolidated Net Sales U.S. — Organic / Comparable Sales Growth (%)(%)
7.9%3.5%2.5%0.9%2.3%8.7%8.8%13.5%11.0%9.0%10.0%7.1%
Total Company Consolidated Net Sales U.S. — Reported Sales Growth (%)(%)
28.0%22.0%2.5%0.9%2.3%8.7%8.4%10.0%10.1%4.7%-2.1%-6.4%
Total Company Consolidated Net Sales — International Revenue ($M)($M)2
7,5097,3776,8907,0767,0706,8666,1906,6336,4336,4436,1186,292
Total Company Consolidated Net Sales International — Organic / Comparable Sales Growth (%)(%)
6.4%5.8%4.6%4.3%7.6%5.8%5.7%8.1%6.5%9.4%11.3%13.4%
Total Company Consolidated Net Sales International — Reported Sales Growth (%)(%)
6.2%7.5%11.3%6.7%9.9%6.6%1.2%5.4%1.7%3.6%5.2%7.2%
Total Company — Organic Sales Growth Excl. COVID-19 Testing (%)(%)
3.8%7.5%7.5%10.1%8.2%9.3%10.8%11.0%
Non-GAAP Adjusted Diluted Earnings Per Share ($/share)($)2
1.421.311.151.501.301.261.091.341.211.140.981.19
GAAP Diluted Earnings Per Share — Reconciliation Table ($/share)($)
0.530.530.611.010.941.010.765.270.940.740.700.91
Specified Items Impact on Diluted EPS ($/share)($)
0.890.780.540.490.360.250.330.270.400.280.28
Non-GAAP Adjusted Net Earnings ($M)($M)7
2,4772,2902,0222,6302,2782,2131,9192,3492,1192,0031,7292,094
GAAP Net Earnings — Reconciliation Table ($M)($M)
9209281,0771,7761,6441,7791,3259,2291,6461,3021,2251,594
Specified Items After-Tax Net Impact ($M)($M)
1,5571,362945854634434594-6,880473701504500
Non-GAAP Adjusted Earnings Before Taxes ($M)($M)
2,9202,7012,3853,0862,7282,6502,2982,7632,4922,3562,0352,435
Non-GAAP Adjusted Gross Margin ($M)($M)
7,4487,3076,2846,5436,3446,3465,9186,2405,9835,8095,5475,722
Non-GAAP Adjusted Research & Development Expense ($M)($M)
892867743706730705689690694657663622
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M)
3,5053,5973,2672,8753,0043,0903,0512,8862,8902,8792,9252,689
Intangible Assets Amortization Expense ($M)($M)5
841658422422420420420465470471472481
Forecasted Annual Intangible Amortization — Year 1 ($M)($M)
2,3002,3001,5001,5001,5001,5001,7001,7001,7001,7001,900
Forecasted Annual Intangible Amortization — Year 2 ($M)($M)
1,8001,8001,2001,2001,2001,2001,5001,6001,6001,6001,700
Forecasted Annual Intangible Amortization — Year 3 ($M)($M)
1,7001,7006507007007001,2001,3001,3001,3001,600
Forecasted Annual Intangible Amortization — Year 4 ($M)($M)
1,5001,5006086006006006687007007001,300
Forecasted Annual Intangible Amortization — Year 5 ($M)($M)
363605700
Effective Tax Rate — Non-GAAP Adjusted (%)(%)1
15.2%15.2%15.2%14.8%16.5%16.5%16.5%15.0%15.0%15.0%15.0%14.0%
Effective Tax Rate — GAAP Reported (%)(%)
25.3%39.1%25.6%24.7%24.6%17.3%25.5%-354.6%15.2%19.0%14.7%11.2%
Quarterly Common Dividend Declared ($/share)($)
0.630.630.630.630.590.590.590.590.550.550.550.55
Total Inventories Net ($M)($M)3
7,3156,9896,4886,7086,9546,6396,1946,8136,8146,8276,570
Finished Goods Inventory ($M)($M)
4,5124,2743,9764,1304,3194,0633,7004,1734,0604,0633,946
Work in Process Inventory ($M)($M)
1,023994904961962890840877880881807
Raw Materials Inventory ($M)($M)
1,7801,7211,6081,6171,6731,6861,6541,7631,8741,8831,817
Property, Plant & Equipment — Gross Carrying Value ($M)($M)5
26,46925,73725,22224,81624,47223,41822,74022,85722,06122,05521,933
Machinery & Equipment — Gross ($M)($M)
17,57115,51715,179
Buildings — Gross ($M)($M)
4,5434,2074,161
Construction in Progress ($M)($M)
2,5672,4882,064
Land ($M)($M)
541528529
Accumulated Depreciation ($M)($M)
13,65713,36013,40613,31213,07712,48612,08212,23611,82811,94811,779
Common Shares Repurchased — Value ($M)($M)1
1,04018301303124369752022304
Common Shares Repurchased — Volume (Million Shares)(M)
00000000000
Defined Benefit Pension Plans — Projected Benefit Obligation ($M)($M)2
9,8809,45010,030
Defined Benefit Pension Plans — Fair Value of Plan Assets ($M)($M)
16,24714,14313,085
Post-Retirement Medical & Dental Plans — Benefit Obligation ($M)($M)
1,3861,1661,181
Abbott India Limited — Revenue from Operations (INR Crores)9
1,8141,7101,7241,7571,7381,6051,6141,6331,5581,4391,437
Abbott India — Operating Profit / EBITDA (INR Crores)
522481463502446429436439391330388
Abbott India — Operating Profit Margin (%)(%)
29.0%28.0%27.0%29.0%26.0%27.0%27.0%27.0%25.0%23.0%27.0%
Abbott India — Operating Expenses (INR Crores)
1,2911,2291,2611,2551,2931,1761,1781,1941,1671,1091,049
Abbott India — Other / Treasury Income (INR Crores)
7576707073767260678156
Abbott India — Depreciation & Amortization (INR Crores)
2019191919181818181818
Abbott India — Profit Before Tax (INR Crores)
572531509546493483488479437390422
Abbott India — Effective Tax Rate (%)(%)
25.0%26.0%26.0%24.0%26.0%24.0%26.0%25.0%25.0%26.0%26.0%
Abbott India — Net Profit (INR Crores)
429395376415366367361359328287311
Abbott India — Earnings Per Share (INR / Share)
202186177195172173170169154135146
Abbott India Limited — Number of Registered Shareholders4
75,76978,32075,86675,80171,19967,58469,93467,89269,44971,58869,38272,252
Abbott India — Promoter (Abbott Parent) Shareholding (%)(%)
75.0%75.0%75.0%75.0%75.0%75.0%75.0%75.0%75.0%75.0%75.0%75.0%
Abbott India — Domestic Institutional Investors (DIIs) Shareholding (%)(%)
9.0%8.8%8.9%9.0%9.1%9.2%8.9%9.0%9.0%8.8%8.9%8.7%
Abbott India — Foreign Institutional Investors (FIIs) Shareholding (%)(%)
0.4%0.4%0.3%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%
Abbott India — Public / Retail Shareholding (%)(%)
15.6%15.9%15.8%15.8%15.7%15.7%15.9%15.9%15.9%16.0%15.9%16.1%
U.S. FDA 510(k) Device Clearances — Abbott5
682598754525
U.S. FDA 510(k) Device Clearances — Total U.S. MedTech Industry
855923756806797886736856767793713877
U.S. FDA Premarket Approvals (PMA Original & Supplements) — Abbott
657570506987539771665492
U.S. FDA Premarket Approvals (PMA) — Total U.S. MedTech Industry
565608567525585588524683538550459656
U.S. FDA Medical Device Recall Events — Abbott
045941701420574
U.S. FDA Enforcement Recall Actions — Abbott
04594175920583
U.S. FDA MAUDE Adverse Event MDR Reports — Abbott Total4
295,931143,86629,40023,68425,29823,39020,97922,37325,01022,31020,46022,102
FDA MAUDE MDR Reports — Device Malfunction (Abbott)
285,131132,39022,05816,58016,53114,83212,63811,98714,45512,09010,65611,988
FDA MAUDE MDR Reports — Patient Injury (Abbott)
10,41311,1207,0756,8578,5388,4108,21210,22010,42810,0699,6579,942
FDA MAUDE MDR Reports — Death (Abbott)
265354259244227145126162124148141161
FDA MAUDE Adverse Event MDR Reports — Total MedTech Industry
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
NIH ClinicalTrials.gov — Cumulative Abbott-Sponsored Clinical Studies1
ClinicalTrials.gov — New Abbott Clinical Studies Started
12491110177141381410
U.S. PPI — Surgical & Medical Instruments Manufacturing (Index)(×)5
163.40162.90161.70159.60157.80156.90157.10155.20154.40154.10153.60151.00
U.S. PPI — Surgical Appliances & Supplies Manufacturing (Index)(×)
269.30263.80253.80251.40249.60249.50248.70245.40245.10243.70240.10238.50
U.S. PPI — Electromedical & Electrotherapeutic Apparatus (Index)(×)
92.8092.1092.0091.6090.7090.3090.1089.5089.3088.4088.3087.80
U.S. CPI — Medical Care Commodities (Index)(×)
404.90410.40416.80417.00416.50416.00412.60415.90414.50408.30410.10
U.S. CPI — Medical Care Services (Index)(×)
654.70650.90647.60638.40630.60623.40619.60613.00611.40605.80597.90
U.S. Census QSS — General Medical & Surgical Hospitals Revenue ($M)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Reportable Segments Total Operating Earnings ($M)($M)
1,6931,3452,2512,0572,0521,6931,9111,8591,6691,3861,780
Medical Devices — Segment Cost of Products Sold ($M)($M)3
1,9251,814-12,0961,7671,7581,598-11,1871,6051,6271,547
Diagnostic Products — Segment Cost of Products Sold ($M)($M)
1,5321,242-8,6501,2901,2241,152-8,6661,2801,2031,188
Nutritional Products — Segment Cost of Products Sold ($M)($M)
1,1481,089-8,0711,2231,1551,124-7,9191,1511,1481,088
Established Pharmaceutical Products — Segment Cost of Products Sold ($M)($M)
650644-4,529714631569-4,263644591584
Medical Devices — Segment Total Assets ($M)($M)4
11,40610,98310,68910,57610,55510,0349,4729,029
Medical Devices — Segment Depreciation & Amortization ($M)($M)
1061009997948882878787
Diagnostic Products — Segment Depreciation & Amortization ($M)($M)
165144136136135126134129129129
Nutritional Products — Segment Depreciation & Amortization ($M)($M)
51504247444243383939
Established Pharmaceutical Products — Segment Depreciation & Amortization ($M)($M)
25302528252325232424
Geographic Revenue — United States ($M)($M)1
5,2164,2744,3834,2994,2764,1684,3414,2023,9343,8463,949
Long-Lived Assets — United States ($M)($M)
11,90010,3008,900
Consolidated Net Sales ($M)($M)11
12,59311,16411,45911,36911,14210,35810,97410,63510,3779,96410,241
Cost of Products Sold ($M)($M)
5,3254,8904,9225,0754,8544,4684,9424,6984,6034,4634,556
GAAP Gross Margin ($M)($M)
6,5446,6105,8526,1155,8745,8685,4705,5675,4675,3035,0295,204
Research & Development Expense ($M)($M)
892767735766725716749713698684700
Selling, General & Administrative Expense ($M)($M)
4,0253,7403,1293,0513,0913,0612,9072,8952,9362,9592,724
Operating Earnings ($M)($M)
1,6931,3452,2512,0572,0521,6931,9111,8591,6691,3861,780
Interest Expense ($M)($M)
351174120121121131136142140141159
Earnings Before Taxes ($M)($M)
1,5241,4492,3582,1802,1501,7782,0301,9401,6071,4361,795
Taxes on Earnings ($M)($M)
596372582536371453-7,199294305211201
Net Earnings ($M)($M)
9281,0771,7761,6441,7791,3259,2291,6461,3021,2251,594
Diluted Earnings Per Common Share ($/share)($)
0.530.610.941.010.760.940.740.70
Weighted-Average Diluted Shares Outstanding (Millions)(M)
1,7431,7471,7491,7511,7471,7481,7511,750
Total Assets ($M)($M)11
109,215110,42986,71384,18183,99981,44881,41474,35673,01772,46773,214
Cash & Cash Equivalents ($M)($M)
5,1046,8038,5227,5116,9516,5327,6167,5586,9876,2846,896
Short-Term Investments ($M)($M)
499492417222331312351230232367383
Trade Accounts Receivable, Net ($M)($M)
8,5998,2107,9298,1387,9727,3276,9257,0516,8546,6056,565
Total Inventories ($M)($M)
7,3156,9896,4886,7086,9546,6396,1946,8136,8146,8276,570
Total Current Assets ($M)($M)
24,51725,50825,99624,83924,46823,15323,65623,80223,11922,37622,670
Net Property & Equipment ($M)($M)
12,81212,37711,81611,50411,39510,93210,65810,62110,23310,10710,154
Goodwill ($M)($M)
35,24435,22124,03523,97123,95223,35923,10823,65823,30823,38323,679
Intangible Assets, Net of Amortization ($M)($M)
17,21117,8755,5265,5985,9206,2616,6477,3527,8278,2968,815
Total Current Liabilities ($M)($M)
17,81418,37716,49614,58213,43913,00414,15714,90213,76014,02113,841
Long-Term Debt ($M)($M)
29,60329,6389,89611,59612,93012,73612,62512,82513,13912,57613,599
Total Shareholders' Investment / Equity ($M)($M)
51,11052,06152,13050,95450,56548,81147,66439,79639,31838,81038,603
Operating Cash Flow ($M)($M)3
2,4881,3153,3152,7872,0471,4172,8682,7051,9601,0253,038
Capital Expenditures ($M)($M)
497399689496502484720556533398755
Dividends Paid ($M)($M)
1,1021,0981,0301,0311,0291,026958960961957888
Stock-Based Compensation Expense ($M)($M)
168317113120142289111117141304114

20 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational KPI Drivers (Groups 1–4): Flagship Continuous Glucose Monitoring (FreeStyle Libre & Lingo) sales and organic growth, all 7 Medical Devices divisions (Diabetes Care, Electrophysiology, Structural Heart, Rhythm Management, Heart Failure, Vascular, Neuromodulation), all 5 Diagnostics divisions (Core Laboratory, Cancer Diagnostics / Exact Sciences acquired March 2026, Rapid & Molecular Diagnostics, and legacy Rapid/Molecular/Point of Care) + COVID-19 testing sales & ex-COVID base growth, Nutritional Products (Pediatric & Adult + WIC state contracts & NEC reserves), and Established Pharmaceuticals (Key Emerging Markets vs. Other Markets).
  • Standalone / Parent-Only Assessment (Step 3 & Step 4): Abbott Laboratories files consolidated financial statements under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary operations are captured directly from self-reported filings in Group 7: 74.99%-owned listed Indian subsidiary Abbott India Limited (NSE: ABBOTINDIA, in INR Crores) and 4 UK operating subsidiaries (UK Gender Pay Gap filings).
  • Period Splitting (Step 4): Missing standalone quarters for CGM revenue (where 10-Q/10-K reported 6M, 9M, and FY cumulative totals) and cash flow statement quarters (Q2–Q4) are derived strictly via 6M − Q1, 9M − 6M, and FY − 9M.

Không hiện vì thiếu các kỳ gần đây (4)

  • FreeStyle Libre Global Patient Count (~6M–7M users) — Disclosed only as approximate bounds ('more than 6 million', 'nearly 7 million') in earnings calls/releases; excluded per Step 5 bound rule.
  • Annual People Reached Globally (>2 billion people / 3 billion lives目标) — Disclosed as bound ('more than 2 billion') in Annual Report / ESG; excluded per Step 5 bound rule.
  • Scope 3 GHG Emissions by Category (ktCO2e) — Only 1–2 years of complete category disaggregation in ESG 2024; excluded due to insufficient multi-period continuity.
  • Diagnostics Legacy Subsegments (Rapid Diagnostics, Molecular Diagnostics, Point of Care) post-FY2025Q4 — Combined into 'Rapid and Molecular Diagnostics' starting Q1 2026; legacy series retained through FY2025Q4 and new combined series tracked from Q1 2026.

Dữ liệu cập nhật 2026-10-29.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Consolidated Financial Statements — Income, Balance Sheet & Cash Flows (Database Context)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Abbott Laboratories

See a number that looks wrong?